Alkermes, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established itself as a leader in the industry, with significant operational presence across North America and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it favourably in the market, with notable achievements in advancing patient care through its proprietary formulations. With a strong emphasis on research and development, Alkermes continues to drive innovation in the biopharmaceutical landscape.
We don't have data for Alkermes, Inc., but we can show you information about their parent organization instead.
View parent company